TARX (Tarsier Pharma) Loans Receivable: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Tarsier Pharma Loans Receivable?

Tarsier Pharma TARX Loans Receivable is $0.00 Mil as of Dec. 2025.

Tarsier Pharma's Loans Receivable for the quarter that ended in Dec. 2025 was $0.00 Mil.

Tarsier Pharma Loans Receivable Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma Loans Receivable Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
Loans Receivable
0.00 0.00 0.00

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable 0.00 0.00 0.00 0.00 0.00

Tarsier Pharma Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
Tarsier Pharma (TARX) has a Loans Receivable of $0.00 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Tarsier Pharma and its competitors.
Is Tarsier Pharma's Loans Receivable too high?
Tarsier Pharma's current Loans Receivable is $0.00 Mil.
How does Tarsier Pharma's Loans Receivable compare to ?
Tarsier Pharma's Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Tarsier Pharma and its competitors. Tarsier Pharma's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsier Pharma stock overvalued right now?
Tarsier Pharma (TARX) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Tarsier Pharma (TARX), the current Loans Receivable is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.